Market revenue in 2024 | USD 105.9 million |
Market revenue in 2035 | USD 468.6 million |
Growth rate | 12.2% (CAGR from 2025 to 2035) |
Largest segment | Ozempic (semaglutide) |
Fastest growing segment | Rybelsus (oral semaglutide) |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2035 |
Quantitative units | Revenue in USD million |
Market segmentation | Ozempic (semaglutide), Wegovy (semaglutide), Rybelsus (oral semaglutide) |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to semaglutide market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 59.77% in 2024. Horizon Databook has segmented the Saudi Arabia semaglutide market based on ozempic (semaglutide), wegovy (semaglutide), rybelsus (oral semaglutide) covering the revenue growth of each sub-segment from 2018 to 2035.
Saudi Arabia’s market is expanding, driven by healthcare reforms and rising obesity-related complications.
Government investments in biotechnology and chronic disease management support semaglutide adoption. Retail and hospital pharmacies are key distribution channels, with growing online pharmacy penetration enhancing patient access.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia semaglutide market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia semaglutide market from 2018 to 2035, including revenue numbers, major trends, and company profiles.
No related statistics found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account